IL2 and type 1 diabetes mellitus: Targeting the IL-2 pathway is logical, as the decrease in Tregs seen during NOD diabetes progression is thought to be due to dysregulated IL-2 production within the pancreatic islets leading to loss in Treg function and survival (158), and IL-2R dysfunction is implicated in development of T1D (9).